INTRODUCTION
============

Colorectal cancer (CRC) represents the third and second most frequently diagnosed cancer in men and women, respectively. However, CRC mortality rates are high in a large number of countries worldwide \[[@b1-kjim-2016-348]\]. In 2012, the Korea Central Cancer Registry contained 28,988 cases of newly diagnosed CRC. The crude incidence rate was an estimated 57.6 (69.3 for men and 45.9 for women) per 100,000 individuals, making CRC the third most frequently diagnosed cancer, after thyroid and gastric cancer \[[@b2-kjim-2016-348]\].

CRC is associated with different anatomical, biological, and clinical characteristics. The subsite-specific incidences of CRC are approximately 25.0%, 5.0%, 5.0%, 22.0%, and 27.0% for ascending colon and cecum, transverse colon, descending colon, sigmoid colon, and the rectum, respectively \[[@b3-kjim-2016-348]\]. Genetic and epigenetic alterations in CRC differ according to the primary tumor location \[[@b4-kjim-2016-348]\]. CRCs associated with germline mutations of the *APC* gene develop in the distal colon in approximately 60.0% of the cases and in the rectum in approximately 25.0% of the cases. High microsatellite instability (MSI) and mismatch repair deficient colon cancers predominantly occur in the right colon \[[@b5-kjim-2016-348],[@b6-kjim-2016-348]\]. Treatment for CRC also differs in the early stages. Rectal cancer requires radio- or chemoradiotherapy, whereas colon cancer does not \[[@b7-kjim-2016-348]\]. However, the treatment for metastatic CRC (mCRC) is usually the same. A mCRC is treated with fluoropyrimidine and either irinotecan or oxaliplatin, which is associated with an increased overall survival (OS) of \> 2.0 years, with the addition of molecularly targeted agents \[[@b8-kjim-2016-348]\]. Vascular endothelial growth factor (VEGF) inhibition with a monoclonal antibody, in combination with first- or second-line chemotherapy, has been shown to prolong survival in mCRC patients \[[@b9-kjim-2016-348],[@b10-kjim-2016-348]\]. Monoclonal antibody inhibition of the epidermal growth factor receptor (EGFR) cetuximab or panitumumab has also been associated with improved patient outcomes, but only in the absence of *RAS* gene mutations \[[@b11-kjim-2016-348],[@b12-kjim-2016-348]\].

A mCRC registry was designed to collect and evaluate data in patients with newly diagnosed primary mCRC. In this study, we aimed to evaluate the influence of the primary tumor location on the metastatic sites, *KRAS* gene mutation status, treatment patterns, and clinical outcomes in mCRC patients.

METHODS
=======

This study was performed by the Colorectal Cancer Committee of the Korean Cancer Study Group (KCSG). The study was approved by the Institutional Review Board of KCSG (KCSG CO12-04) and each of the 22 participating institutions and performed in accordance with the principles of the Declaration of Helsinki. The informed consent was waived. The demographic data and clinical information of patients who were newly diagnosed with mCRC between January 2009 and December 2011 were reviewed using web-based electronic case report forms. Patients aged ≥ 18 years who had pathologically confirmed adenocarcinoma with stage IV mCRC at initial diagnosis were enrolled in this study. Patients who had squamous cell carcinoma, non-Hodgkin's lymphoma, and neuroendocrine tumors (among others), or recurrences of early-stage CRC were excluded. Patient demographic data and information on primary tumor location, metastatic sites, treatment patterns, and clinical outcomes were collected by a physician or designated representative.

Primary tumor location was divided into the right colon, left colon, and the rectum. Tumors originating in the cecum, ascending colon, and proximal two-thirds of the transverse colon were categorized as cancers arising in the right colon. Tumors originating in the distal third of the transverse colon and sigmoid colon were categorized as cancers arising in the left colon. Because surgical resection of the primary mCRC had been performed in selected patients, the precise location of the primary tumor was difficult to ascertain, especially in the transverse colon, rectosigmoid colon, and upper rectum. Therefore, patients with transverse colon cancer were excluded and we arbitrarily defined rectal cancer as that originating in an approximate 15.0 cm region from the anal verge.

The *KRAS* gene mutations in this report refer to mutations in codon 12 or 13 in exon 2. *KRAS* genetic testing was performed using samples of paraffin-embedded tumor tissues that were sent to a laboratory for analysis using the established methods of each institution, including peptide nucleic acid-mediated real-time polymerase chain reaction clamping, direct sequencing, and pyrosequencing.

Statistical analyses
--------------------

The data were summarized using descriptive statistics. Continuous variables are represented by the frequency distribution, median, standard deviation, and extreme values. Categorical variables are represented by percentage frequency of each modality and 95% confidence intervals (CIs). For categorical data, group comparisons were performed by an analysis of variance provided there was a reasonably normal distribution. Otherwise, chi-square or Fisher exact tests were performed. Progression- free survival (PFS) was estimated from the date of commencing treatment to the date of disease progression, or the date of death or last follow-up. OS was defined as the time from the date of pathological diagnosis to the date of death from any cause. PFS and OS were analyzed using the Kaplan-Meier method. For continuous data, analyses of variance tests were performed. A Cox proportional hazards regression model was used in the multivariate analysis of factors of OS that were significantly different in the univariate analysis. All statistical analyses were conducted using SPSS for Windows software version 19.0 (IBM Corp., Armonk, NY, USA). A *p* \< 0.05 was considered statistically significant.

RESULTS
=======

Patient characteristics
-----------------------

In total, 1,166 patients were enrolled by 22 institutional members of the KCSG Colorectal Cancer Committee. Transverse colon cancers were difficult to divide into right and left colon cancers in the absence of surgery. Therefore, we excluded 51 patients with transverse colon cancer from this study. Of the remaining 1,115 patients, 685 (61.4%) were men and 430 (38.6%) were women. The baseline demographics and disease characteristics are summarized in [Table 1](#t1-kjim-2016-348){ref-type="table"}. Seven hundred and twenty-seven patients (65.2%) presented with metastatic colon cancer, including 244 patients (21.9%) with right colon cancer, 483 patients (43.3%) with left colon cancer, and 388 patients (34.8%) with rectal cancer. The median age of all patients was 62 years (range, 31 to 94). The most common symptom of mCRC was abdominal pain, which occurred in 462 patients (41.4%). However, 95 patients (8.5%) were asymptomatic. Active treatment (surgical resection with or without chemotherapy, or chemotherapy alone) was performed in 1,003 patients (90.0%). The remaining 112 patients received conservative care, such as symptomatic control of the intestinal obstruction by colostomy, stenting, palliative surgery, or radiation therapy.

Metastatic patterns according to primary tumor location
-------------------------------------------------------

The most frequent metastatic sites of mCRC include the liver, lungs, extra-regional lymph nodes, and peritoneum. More than half of the patients (52.6%) had a single metastatic site, in ascending order, in the liver (35.9%), lungs (4.7%), and peritoneum (4.3%). The liver was the most frequent metastatic site (75.0%), with or without other sites. Liver and lung metastases arose more frequently from primary left colon and rectal cancer than right colon cancer (*p* = 0.005 and *p* = 0.006, respectively). Peritoneal and ovarian metastases arose more frequently from primary right and left colon cancer than rectal cancer (*p* \< 0.001 and *p* \< 0.05, respectively) ([Table 2](#t2-kjim-2016-348){ref-type="table"}). In contrast, no significant differences were observed between tumors originating from the right colon, left colon, or the rectum with respect to other rarer metastatic sites (e.g., the brain, bone, and spleen).

Treatment for metastatic colorectal cancer
------------------------------------------

The mCRC treatment did not differ according to primary tumor location. During this study, the use of anti-EGFR or anti-VEGF agents was limited due to the coverage of national insurance reimbursement. The majority of the patients were treated with sequential oxaliplatin- based or irinotecan-based combination chemotherapy, or an alternative sequence. The median number of chemotherapy regimens that were used was 2 (range, 1 to 7). One thousand and three patients (90.0%) patients received first-line chemotherapy, and 728 patients (65.2%) received second-line chemotherapy. The median number of cycles of chemotherapy for first- and second-line chemotherapy was 8 (range, 1 to 54) and 5 (range, 1 to 32), respectively ([Table 3](#t3-kjim-2016-348){ref-type="table"}). Third-line chemotherapy was administered to 429 patients (38.5%). Single-agent capecitabine was used in the majority (30.3%) of these patients. In this study, 14.4%, 8.6%, 8.9%, 10.1%, and 13.2% of patients who received first-, second-, third-, fourth-, and fifth-line chemotherapy, respectively, were involved in a clinical trial.

Signs or symptoms of an intestinal obstruction were observed in 643 patients (57.7%) ([Table 1](#t1-kjim-2016-348){ref-type="table"}). Palliative or curative surgery, stenting, a combination of palliative or curative surgery and stenting, or an alternative method (e.g., conservative therapy, radiation therapy, chemotherapy, or concurrent chemoradiotherapy) was used to treat the intestinal obstruction in 352 (31.6%), 176 (15.8%), 43 (3.9%), and 72 patients (6.4%), respectively.

Oncological outcomes according to primary tumor location and chemotherapy with molecularly targeted agents
----------------------------------------------------------------------------------------------------------

The median OS of all mCRC patients was 17.8 months (95% CI, 16.7 to 18.9), although differences were observed according to primary tumor location ([Table 4](#t4-kjim-2016-348){ref-type="table"}). The median OS of patients with tumors originating in the right colon was significantly shorter than that of patients whose tumors had originated in the left colon or rectum (13.7 months \[95% CI, 12.0 to 15.5\] vs. 18.0 months \[95% CI, 16.3 to 19.7\] or 19.9 months \[95% CI, 18.5 to 21.3\], respectively; *p* = 0.003) ([Fig. 1](#f1-kjim-2016-348){ref-type="fig"}).

Chemotherapy with molecularly targeted agents
---------------------------------------------

The majority of patients were treated with several chemotherapy regimens. Compared to patients who were not administered chemotherapy (i.e., receiving best supportive care only), a survival benefit was observed in the chemotherapy group, with a median OS of 19.2 (95% CI, 18.1 to 20.3) months compared to 3.2 (95% CI, 1.5 to 4.9) months for the best supportive care group ([Table 4](#t4-kjim-2016-348){ref-type="table"}). Despite anti-EGFR and anti-VEGF agents being restricted by the coverage of national insurance reimbursement, the use of anti-EGFR and anti-VEGF agents was associated with a prolonged survival. The median OS of patients who had received combination chemotherapy with anti-EGFR or anti-VEGF agents was significantly longer than that of patients who had received combination chemotherapy alone (22.0 months \[95% CI, 19.5 to 24.5\] vs. 18.5 months \[95% CI, 17.2 to 19.7\], respectively; *p* \< 0.05). This was particularly the case for patients with primary tumors originating from the left colon or rectum ([Fig. 2](#f2-kjim-2016-348){ref-type="fig"}). For patients treated with first-line chemotherapy, the median PFS was comparable to the median OS (7.0 months \[95% CI, 6.5 to 7.5\] vs. 8.9 months \[95% CI, 8.1 to 9.8\] for the chemotherapy alone and chemotherapy with molecularly targeted agent groups, respectively; *p* = 0.002). The effect of chemotherapy with molecularly targeted agents was more pronounced in left colon and rectal cancer patients than right colon cancer patients (*p* \< 0.05). However, for patients treated with second-line chemotherapy, the effect of molecularly targeted agents was reduced and no significant differences were observed with respect to primary tumor location.

*KRAS* mutation status and primary tumor location
-------------------------------------------------

The *KRAS* genetic testing was performed in 516 of the 1,115 patients (46.3%) included in this study. At the time, only exon 2 was screened due to the definition of a wildtype *KRAS* gene. *KRAS* genetic testing was performed by peptide nucleic acid-mediated real-time polymerase chain reaction clamping, direct sequencing, or pyrosequencing. The mutant *KRAS* gene was detected in 179 patients (34.7%) and was more frequently observed in patients with primary right colon cancer (*p* = 0.004) ([Table 5](#t5-kjim-2016-348){ref-type="table"}). Codon 12 mutations were detected in 132 patients (73.7%) and codon 13 mutations were detected in 42 patients (23.5%). The *KRAS* mutation status was unknown for the remaining five patients (2.8%). In this study, the *KRAS* mutation status itself did not influence the median OS. However, in patients with the wild-type *KRAS* gene, chemotherapy with molecularly targeted agents and the primary tumor location correlated with OS ([Tables 6](#t6-kjim-2016-348){ref-type="table"} and [7](#t7-kjim-2016-348){ref-type="table"}). Patients with primary left colon or rectal tumors that expressed the wild-type *KRAS* gene had a significant longer median OS than patients with primary right colon tumors (21.7 months \[95% CI, 17.6 to 25.8\] or 21.6 months \[95% CI, 18.6 to 22.7\] vs. 15.6 months \[95% CI, 12.6 to 18.5\], respectively; *p* = 0.008).

Surgical resection and primary tumor location
---------------------------------------------

Surgical resection of the primary and metastatic tumors was associated with a prolonged survival. Curative resections were performed in 218 patients (19.6%). One hundred and thirty-eight patients (12.4%) underwent surgical resection as the initial treatment and 80 patients (7.2%) underwent surgical resection during first- or second-line chemotherapy. Curative resections were usually performed by resecting the primary tumor and metastatic tumors with or without radiofrequency ablation. Palliative resections were performed in 330 patients (29.6%). The majority of palliative resections were primary tumor resections ([Table 8](#t8-kjim-2016-348){ref-type="table"}). Irrespective of whether the surgical resections were curative, tumor resection was associated with a more favorable prognosis. The median OS was 38.9 months (95% CI, 34.0 to 43.8) for patients who had undergone curative resection, 19.7 months (95% CI, 18.0 to 21.4) for patients who had undergone palliative resection, and 12.1 months (95% CI, 11.2 to 13.1) for patients who did not undergo surgical resection (*p* = 0.007). However, in patients who underwent curative or palliative resection, no significant differences in OS were observed with respect to primary tumor location (*p* = 0.224 and *p* = 0.078, respectively).

Difference in the numbers and pattern of metastatic sites
---------------------------------------------------------

The number and pattern of metastatic sites were associated with survival. In patients with a single metastatic site, the median OS differed according to the metastatic site. The median OS was 19.8 (95% CI, 17.5 to 22.1), 27.8 (95% CI, 23.2 to 32.4), 18.0 (95% CI, 11.0 to 25.0), 24.9 (95% CI, 21.5 to 28.3), 4.1 (95% CI, 2.5 to 5.7), and 28.4 months (95% CI, 26.5 to 30.3) months for patients with liver, lung, peritoneal, extra-regional lymph node, bone and ovarian metastases alone, respectively (*p* = 0.031). The OS of a patient with brain metastasis alone was 15.7 months. A comparison of the different metastatic sites revealed that the survival of patients with peritoneal metastasis was significantly poorer than the survival of patients with liver (*p* \< 0.05), lung (*p* = 0.002), or extra-regional lymph node (*p* = 0.001) metastases. In contrast, no significant differences were observed for patients with bone or ovarian metastases (*p* = 0.481 and *p* = 0.124, respectively).

The number of metastatic sites exhibited a statistically significant effect on survival. The median OS of patients with a single metastatic site, including those with a solitary metastasis, was significantly longer than that of patients with multiple metastatic sites (21.2 months \[95% CI, 19.2 to 23.2\] vs. 16.7 months \[95% CI, 15.0 to 18.4\] or 13.1 months \[95% CI, 10.8 to 15.4\] for 2 and ≥ 3 metastatic sites, respectively; *p* \< 0.001) ([Fig. 3](#f3-kjim-2016-348){ref-type="fig"}).

Prognostic factors
------------------

In the univariate analysis, age, the presence of an underlying disease, Eastern Cooperative Oncology Group (ECOG) performance status (PS), the number of metastatic sites, the use of molecularly targeted agents, surgical resection, and primary tumor location correlated with OS. Due to the extent of missing data for the ECOG PS, the use of molecularly targeted agents, and *KRAS* mutation status, these factors were excluded from the multivariate analysis. In the multivariate analysis, the number of metastatic sites, surgical resection (curative and palliative), and primary tumor location were associated with OS ([Table 9](#t9-kjim-2016-348){ref-type="table"}).

DISCUSSION
==========

In this study, we demonstrate that the primary tumor location influences the metastatic sites and prognosis of patients with mCRC. The pattern of metastasis differed according to primary tumor location. Right colon cancer metastasized more frequently to the peritoneum and ovaries and left colon and rectal cancer metastasized more frequently to the lungs. This difference was also reported in recurrence patterns after curative resection or the initial presentation of metastatic disease. Colon cancer patients presented more frequently with intraabdominal metastases, including peritoneal, omental, and ovarian metastases. Left colon cancer patients were associated with an increased risk of metastatic spread to the liver, whereas rectal cancer patients were associated with an increased risk of local recurrence and metastatic spread to the extra-abdominal sites, including the lungs and brain \[[@b13-kjim-2016-348]-[@b16-kjim-2016-348]\]. These differences affected the initial evaluation of CRC and clinical practice. Although limited evidence exists regarding the pattern of spread of CRCs, there are several potential explanations for the differences in metastatic patterns, including differences in tumor genetics, biology, and histology \[[@b16-kjim-2016-348],[@b17-kjim-2016-348]\], as well as, anatomically distinct and discrete lymphatic and vascular drainage regions \[[@b18-kjim-2016-348]\].

We have previously established that chemotherapy with or without molecularly targeted agents is associated with prolonged survival in patients with mCRC \[[@b8-kjim-2016-348]- [@b12-kjim-2016-348]\]. In this study, we also demonstrate that the survival of patients with mCRC differs according to the primary tumor location, with a median OS of 13.7, 18.0, and 19.9 months for the right colon, the left colon, and the rectum, respectively. Moreover, in patients who received chemotherapy with molecularly targeted agents the survival benefits were more pronounced for those with tumors originating in the left colon and rectum compared to those with tumors originating in the right colon ([Table 7](#t7-kjim-2016-348){ref-type="table"}). Although controversial, several studies \[[@b19-kjim-2016-348]-[@b21-kjim-2016-348]\] have shown that there may be a survival difference between patients with left and right colon cancer. Meguid et al. \[[@b19-kjim-2016-348]\]. and Benedix et al. \[[@b20-kjim-2016-348]\] reported that patients with right colon cancer had a poorer prognosis than patients with left colon cancer. However, Weiss et al. \[[@b21-kjim-2016-348]\] reported no significant differences in survival between patients with right and left colon cancer. Because these studies focused mainly on early-stage colon cancer, rectal cancer was excluded, due to the different treatments for localized disease. Patients with mCRC were relatively few in number and the pathological information on the tumors was limited. Thus, the influences of the primary tumor location on the clinical outcomes of patients with mCRC remains controversial.

More recently, responses to chemotherapy with molecularly targeted agents have been shown to differ according to primary tumor location. The addition of bevacizumab to combination chemotherapy for mCRC could benefit patients with primary left colon tumors \[[@b22-kjim-2016-348],[@b23-kjim-2016-348]\]. In addition, the anti-EGFR agent, cetuximab, could be beneficial in the treatment of patients with primary left colon tumors \[[@b24-kjim-2016-348],[@b25-kjim-2016-348]\]. In this study, *KRAS* genetic testing was performed in selected mCRC patients, due to the limited coverage of national insurance reimbursement. *KRAS* mutation status differed according to the primary tumor location. *KRAS* gene mutations occurred more frequently in patients with right colon cancer. In patients, whose tumors expressed the wild-type *KRAS* gene, the prognosis was significantly better for left colon and rectal cancer patients than right colon cancer patients. These findings were consistent with those of recently published studies. In the NCIC-CTC-CO.17 trial \[[@b26-kjim-2016-348]\], the efficacy of cetuximab in chemorefractory mCRC patients was significantly higher for those with tumors originating in the left colon. The median PFS for cetuximab-treated patients with primary tumors originating in the left and right colon was 5.4 and 1.9 months, respectively (*p* = 0.002). An analysis of the AIO KRK-0104 trial comparing first-line therapies using cetuximab, capecitabine, and irinotecan with cetuximab, capecitabine, and oxaliplatin \[[@b24-kjim-2016-348]\] reported that patients with primary tumors originating in the left colon had a longer OS and PFS compared to patients whose primary tumors had originated in the right colon.

CRC is a heterogeneous disease with respect to molecular carcinogenesis and morphological multistep pathways. Molecular alterations in CRC may exert their effects through three major pathways: MSI, chromosomal instability (CIN), and CpG island methylator phenotype (CIMP). These pathways illustrate alterations of genes and critical pathways, including defects of DNA mismatch repair genes, *APC* gene with Wnt signaling activation, *TP53* gene with inactivation of p53 pathway, *RAS* and *BRAF* gene with mitogen-activated protein kinase signaling pathway, *PI3KCA* gene with PIK3 signaling, inactivation of transforming growth factor β pathway, epithelial-to-mesnechymal transition genes and *MYC* gene amplification, and among others \[[@b27-kjim-2016-348],[@b28-kjim-2016-348]\]. Moreover, these genetic alterations affect morphological multistep pathways, such as the classic adenoma-carcinoma and serrated neoplasia pathways. These alterations can occur individually or in combination, resulting in the growth of tumors with different clinical and morphological characteristics \[[@b6-kjim-2016-348],[@b29-kjim-2016-348]-[@b31-kjim-2016-348]\]. Although CIN predominantly occurs in sporadic tumors, irrespective of their anatomical site, sporadic tumors harboring MSIs are localized, especially in the proximal colon \[[@b6-kjim-2016-348],[@b32-kjim-2016-348],[@b33-kjim-2016-348]\]. The majority of CIMP-high tumors are associated with MSI, the proximal colon, and *KRAS* and *BRAF* mutation \[[@b34-kjim-2016-348]\]. The clinical characteristics of CIMP CRC patients have been compared to those of CRC patients with MSI. The prognosis of CRC patients with MSI-high tumors is more favorable compared to the prognosis of CRC patients with CIN \[[@b35-kjim-2016-348]\]. However, the CIMP-high tumors are associated with reduced colon cancer mortality rates. Additionally, *BRAF* mutation status is frequently identified in tumors with the CIMP-high tumors as being associated with a high colon cancer specific mortality \[[@b36-kjim-2016-348],[@b37-kjim-2016-348]\]. In the present study, although the molecular characteristics of CRC (e.g., *BRAF* mutation, CIMP, and MSI status) could not be evaluated, the prognosis of patients with right colon cancer was poorer compared to that of patients with left colon or rectal cancer. It may be related to these molecular alterations and clinical characteristics that, at the time of initial diagnosis, metastatic right colon cancer is associated with a greater tumor burden than left colon or rectal cancer.

Surgical resection is the treatment of choice for patients with resectable mCRC \[[@b38-kjim-2016-348]\]. However, palliative resection of the primary tumor in mCRC is controversial. Although selection bias was present, several retrospective analyses \[[@b39-kjim-2016-348],[@b40-kjim-2016-348]\] have demonstrated that palliative resection of the primary tumor is associated with improved survival, especially in relatively young patients with a good PS and tumors that were not poorly differentiated. Our study also revealed that tumor resection, whether curative or palliative, improved the survival of patients with primary tumors at any location. Clinical trials are needed to validate these finding.

KEY MESSAGE
===========

1\. Primary tumor location inf luences the metastatic sites and prognosis of patients with metastatic colorectal cancer.

2\. The effect of chemotherapy with molecularly targeted agents is more pronounced in primary left side tumor location.

3\. Surgical resection of the tumor (curative or palliative) may be influenced the survival.
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###### 

Baseline characteristics of patients with metastatic colorectal cancer

  Characteristic                                          Primary tumor location   *p* value                                 
  ------------------------------------------------------- ------------------------ ------------- ------------- ------------- ---------------------------------------------------------
  Age, yr                                                 62 (31--94)              66 (31--94)   62 (31--88)   60 (32--87)   
  Sex                                                                                                                        
   Male                                                   685 (61.4)               130 (53.3)    289 (59.8)    266 (68.6)    
   Female                                                 430 (38.6)               114 (46.7)    194 (40.2)    122 (31.4)    \< 0.001^[a](#tfn1-kjim-2016-348){ref-type="table-fn"}^
  Symptoms                                                                                                                   
   Abdominal pain                                         462 (41.4)               154 (63.1)    210 (43.5)    98 (25.3)     \< 0.001^[a](#tfn1-kjim-2016-348){ref-type="table-fn"}^
   Bleeding                                               316 (28.3)               22 (9.0)      118 (24.4)    176 (55.7)    \< 0.001^[a](#tfn1-kjim-2016-348){ref-type="table-fn"}^
   Constipation                                           223 (20.0)               27 (11.1)     107 (22.2)    89 (22.9)     \< 0.001^[a](#tfn1-kjim-2016-348){ref-type="table-fn"}^
   Weight loss                                            142 (12.7)               39 (16.0)     52 (10.8)     51 (13.1)     0.131
   Bowel habit change                                     116 (10.4)               14 (5.7)      46 (9.5)      56 (14.4)     0.002^[a](#tfn1-kjim-2016-348){ref-type="table-fn"}^
   Other^[b](#tfn2-kjim-2016-348){ref-type="table-fn"}^   169 (15.2)               38 (15.6)     73 (15.1)     58 (14.9)     0.977
   Asymptomatic                                           95 (8.5)                 21 (8.6)      40 (8.3)      34 (8.8)      0.800
  ECOG PS                                                                                                                    
   0                                                      157 (14.1)               41 (16.8)     70 (14.5)     46 (11.9)     
   1                                                      430 (38.6)               91 (37.3)     163 (33.7)    176 (45.4)    
   2                                                      57 (5.1)                 16 (6.6)      28 (5.8)      13 (3.8)      
   ≥ 3                                                    18 (1.6)                 3 (1.2)       12 (2.5)      3 (0.8)       
   NA                                                     453 (40.6)               93 (38.1)     210 (43.5)    150 (38.7)    0.023^[a](#tfn1-kjim-2016-348){ref-type="table-fn"}^
  Histological subtype                                                                                                       
   ADC                                                    1,089 (97.7)             230 (94.3)    478 (99.0)    381 (98.2)    
   MAC                                                    18 (1.6)                 10 (4.1)      3 (0.6)       5 (1.3)       
   SRCC                                                   8 (0.7)                  4 (1.6)       2 (0.4)       2 (0.5)       0.011^[a](#tfn1-kjim-2016-348){ref-type="table-fn"}^
  Histology                                                                                                                  
   Well differentiated                                    212 (19.0)               37 (15.2)     95 (19.7)     80 (20.6)     
   Moderately differentiated                              693 (62.2)               144 (59.0)    311 (64.4)    238 (34.3)    
   Poorly differentiated                                  126 (11.3)               36 (14.8)     46 (9.5)      44 (11.3)     
   Unknown                                                61 (5.5)                 15 (6.1)      26 (5.4)      20 (5.2)      
   NA                                                     23 (2.0)                 12 (4.9)      5 (1.0)       6 (1.5)       0.010^[a](#tfn1-kjim-2016-348){ref-type="table-fn"}^
  Metastatic sites                                                                                                           
   1                                                      586 (52.6)               130 (53.3)    244 (50.5)    212 (54.6)    
   2                                                      354 (31.7)               72 (29.5)     157 (32.5)    125 (32.2)    
   ≥ 3                                                    175 (15.7)               42 (17.2)     82 (17.0)     51 (13.1)     0.448

Values are presented as median (range) or number (%).

ECOG, Eastern Cooperative Oncology Group; PS, performance status; NA, not available; ADC, adenocarcinoma; MAC, mucinous adenocarcinoma; SRCC, signet-ring cell carcinoma.

*p* \< 0.05.

Anal pain, low stool caliber, abdominal mass.

###### 

Metastatic patterns according to the primary tumor location

  Metastatic site             Primary tumor location   *p* value                              
  --------------------------- ------------------------ ------------ ------------ ------------ ---------------------------------------------------------
  Liver                       836 (75.0)               170 (69.7)   385 (79.7)   281 (72.4)   0.005^[a](#tfn3-kjim-2016-348){ref-type="table-fn"}^
  Extra-regional lymph node   347 (31.1)               78 (32.0)    145 (30.0)   124 (32.0)   0.786
  Lung                        333 (29.9)               55 (22.5)    144 (29.8)   134 (34.5)   0.006^[a](#tfn3-kjim-2016-348){ref-type="table-fn"}^
  Peritoneum                  180 (16.1)               70 (28.7)    79 (16.4)    31 (8.0)     \< 0.001^[a](#tfn3-kjim-2016-348){ref-type="table-fn"}^
  Bone                        77 (6.9)                 11 (4.5)     34 (7.0)     32 (8.2)     0.194
  Ovary                       30 (2.7)                 7 (2.9)      19 (3.9)     4 (1.0)      0.031^[a](#tfn3-kjim-2016-348){ref-type="table-fn"}^
  Brain                       9 (0.8)                  1 (0.4)      4 (0.8)      4 (1.0)      0.695

Values are presented as number (%).

*p* \< 0.05.

###### 

Characteristics of the first- and second- line chemotherapy regimen

  Characteristic                                                              Chemotherapy regimen   
  --------------------------------------------------------------------------- ---------------------- ------------
  No. of cycles                                                               8 (1--54)              5 (1--32)
   ≤ 12                                                                       866 (86.3)             668 (91.8)
   \> 12                                                                      137 (13.7)             60 (8.2)
  Chemotherapy regimen                                                                               
   Oxaliplatin-based regimen^[a](#tfn4-kjim-2016-348){ref-type="table-fn"}^   550 (54.8)             141 (19.4)
   Irinotecan-based regimen^[b](#tfn5-kjim-2016-348){ref-type="table-fn"}^    126 (12.5)             365 (50.1)
   Anti-EGFR agents^[c](#tfn6-kjim-2016-348){ref-type="table-fn"}^            41 (4.1)               30 (4.1)
   Anti-VEGF agents^[d](#tfn7-kjim-2016-348){ref-type="table-fn"}^            138 (13.7)             61 (8.4)
   Capecitabine                                                               57 (5.7)               48 (6.6)
   Other                                                                      93 (9.2)               83 (11.4)

Values are presented as median (range) or number (%).

EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor.

5-Fluorouracil/leucovorin/oxaliplatin or capecitabine/oxaliplatin.

5-Fluorouracil/leucovorin/irinotecan or capecitabine/irinotecan.

Cetuximab or panitumumab.

Bevacizumab.

###### 

OS and PFS according to primary tumor location and treatment regimen

  Characteristic                                                                        Primary tumor location   *p* value                                                   
  ------------------------------------------------------------------------------------- ------------------------ ------------------- ------------------- ------------------- ------------------------------------------------------
  OS, mon                                                                               17.8 (16.7--18.9)        13.7 (12.0--15.5)   18.0 (16.3--19.7)   19.9 (18.5--21.3)   0.003^[a](#tfn8-kjim-2016-348){ref-type="table-fn"}^
   Treatment regimen^[b](#tfn9-kjim-2016-348){ref-type="table-fn"}^                     19.2 (18.1--20.3)        16.2 (14.0--18.3)   19.4 (17.9--21.0)   20.8 (19.5--22.1)   0.086
    Chemotherapy with targeted agents^[c](#tfn10-kjim-2016-348){ref-type="table-fn"}^   22.0 (19.5--24.5)        17.2 (12.4--22.0)   25.3 (20.9--29.7)   22.0 (17.2--26.8)   0.018^[a](#tfn8-kjim-2016-348){ref-type="table-fn"}^
    Chemotherapy without targeted agents                                                18.5 (17.2--19.7)        15.6 (13.1--18.1)   17.9 (15.8--20.0)   20.1 (18.8--21.4)   0.166
    Best supportive care                                                                3.2 (1.5--4.9)           2.5 (0.4--4.6)      5.4 (2.2--8.6)      2.8 (0.0--6.5)      0.122
  PFS, mon                                                                                                                                                                   
   First-line chemotherapy                                                              7.6 (7.1--8.0)           7.4 (6.6--8.2)      7.8 (7.2--8.3)      7.5 (6.8--8.2)      0.265
    Chemotherapy with targeted agents^[c](#tfn10-kjim-2016-348){ref-type="table-fn"}^   8.9 (8.1--9.8)           7.5 (5.7--9.3)      9.5 (8.4--10.7)     8.7 (6.8--10.5)     0.023^[a](#tfn8-kjim-2016-348){ref-type="table-fn"}^
    Chemotherapy without targeted agents                                                7.0 (6.5--7.5)           7.1 (6.2--8.1)      6.6 (5.9--7.3)      7.0 (6.5--7.5)      0.809
   Second-line chemotherapy                                                             3.7 (3.3--4.0)           3.5 (2.7--4.2)      3.6 (3.0--4.2)      3.9 (3.3--4.0)      0.225
    Chemotherapy with targeted agents^[c](#tfn10-kjim-2016-348){ref-type="table-fn"}^   4.4 (3.8--5.0)           3.9 (2.3--5.4)      4.8 (3.9--5.7)      4.1 (3.0--5.2)      0.092
    Chemotherapy without targeted agents                                                3.7 (3.3--5.0)           3.9 (2.3--5.4)      4.8 (3.9--5.7)      4.1 (3.0--5.2)      0.712

Values are presented as median (range).

OS, overall survival; PFS, progression-free survival.

*p* \< 0.05.

Patients were treated by surgical resection with or without chemotherapy or chemotherapy alone.

Patients were treated by chemotherapy with anti-epidermal growth factor receptor and/or anti-vascular endothelial growth factor agents.

###### 

*KRAS* mutation status according to primary tumor location

                           Primary tumor location   *p* value                             
  ------------------------ ------------------------ ----------- ------------ ------------ -------------------------------------------------------
  *KRAS* mutation status   516                      100         246          170          
   Wild-type               337 (65.3)               51 (51.0)   170 (69.1)   116 (68.2)   
   Mutant                  179 (34.7)               49 (49.0)   76 (30.9)    54 (31.8)    0.004^[a](#tfn11-kjim-2016-348){ref-type="table-fn"}^
  *KRAS* mutation site     179                      49          76           54           
   Codon 12                132 (73.7)               34 (69.4)   58 (73.6)    40 (74.1)    
   Codon 13                42 (23.5)                14 (28.6)   16 (21.1)    12 (22.2)    
   Unknown                 5 (2.8)                  1 (2.0)     2 (2.6)      2 (3.7)      0.873

Values are presented as number (%).

*p* \< 0.05.

###### 

OS and PFS according to primary tumor location and *KRAS* mutation status

  Characteristic             Primary tumor location   *p* value                                                               
  -------------------------- ------------------------ ----------- ------------------- ------------------- ------------------- -------------------------------------------------------
  OS, mon                                                                                                                     
   Wild-type *KRAS*          20.6 (18.5--22.7)        0.310       15.6 (12.6--18.5)   21.7 (17.6--25.8)   21.6 (18.6--22.7)   0.008^[a](#tfn12-kjim-2016-348){ref-type="table-fn"}^
   Mutant *KRAS*             20.7 (18.7--22.8)                    17.5 (13.2--21.8)   20.8 (18.0--23.6)   21.0 (15.6--26.4)   0.689
  First-line chemotherapy                                                                                                     
   Overall PFS, mon          7.6 (7.2--8.0)                       7.4 (6.6--8.2)      7.8 (7.2--8.3)      7.5 (6.8--8.0)      0.265
    Wild-type *KRAS*         8.2 (7.5--8.9)                       7.4 (5.0--9.7)      8.6 (7.9--9.3)      8.5 (7.3--9.7)      0.077
    Mutant *KRAS*            8.3 (7.5--9.2)           0.692       8.3 (6.4--10.3)     7.8 (6.1--9.5)      8.0 (6.4--9.6)      0.892
  Second-line chemotherapy                                                                                                    
   PFS, mon                  3.7 (3.3--4.0)                       3.5 (2.7--4.2)      3.6 (3.0--4.2)      3.9 (3.3--4.5)      0.225
    Wild-type *KRAS*         4.1 (3.5--4.7)                       3.1 (2.0--4.2)      3.8 (2.7--4.9)      4.8 (3.5--4.7)      0.044^[a](#tfn12-kjim-2016-348){ref-type="table-fn"}^
    Mutant *KRAS*            3.5 (2.8--4.2)           0.259       3.7 (2.4--5.0)      2.6 (1.4--3.7)      3.7 (2.7--4.7)      0.223

Values are presented as median (range).

OS, overall survival; PFS, progression-free survival.

*p* \< 0.05.

###### 

OS and PFS according to chemotherapy regimen and *KRAS* mutation status

  Characteristic              Chemotherapy        *p* value           
  --------------------------- ------------------- ------------------- -------------------------------------------------------
  OS, mon                                                             
   Wild-type *KRAS*           24.0 (20.6--26.7)   18.9 (17.2--20.7)   0.015^[b](#tfn14-kjim-2016-348){ref-type="table-fn"}^
   Mutant *KRAS*              21.8 (16.8--26.7)   20.1 (18.1--22.1)   0.670
  PFS, mon                                                            
   First-line chemotherapy                                            
    Wild-type *KRAS*          9.0 (7.9--10.1)     7.6 (6.4--8.7)      0.063
    Mutant *KRAS*             9.1 (7.6--10.7)     7.8 (6.3--9.2)      0.093
   Second-line chemotherapy                                           
    Wild-type *KRAS*          4.6 (3.7--5.5)      3.5 (2.6--4.6)      0.128
    Mutant *KRAS*             4.4 (2.7--4.2)      3.1 (2.3--4.0)      0.006^[b](#tfn14-kjim-2016-348){ref-type="table-fn"}^

Values are presented as median (range).

OS, overall survival; PFS, progression-free survival.

Anti-epidermal growth factor receptor and anti-vascular endothelial growth factor agents.

*p* \< 0.05.

###### 

Surgical outcome according to the primary tumor location

  Characteristic        Primary tumor location   *p* value                                                   
  --------------------- ------------------------ ------------------- ------------------- ------------------- -------------------------------------------------------
  Curative surgery      218 (19.6)               36 (16.5)           93 (42.7)           89 (40.8)           
  Palliative surgery    330 (29.6)               87 (26.4)           142 (43.0)          101 (30.6)          
  OS, mon                                                                                                    
   Curative surgery     38.9 (34.0--43.8)        38.9 (25.0--52.8)   41.8 (34.2--49.3)   35.0 (27.8--42.2)   0.224
   Palliative surgery   19.7 (18.0--21.4)        16.6 (14.5--18.6)   19.7 (17.1--22.3)   21.2 (18.1--21.4)   0.078
   None                 12.1 (11.2--13.1)        9.9 (6.3--13.5)     11.5 (9.6--13.5)    13.2 (10.9--15.6)   0.019^[a](#tfn15-kjim-2016-348){ref-type="table-fn"}^

Values are presented as number (%) or median (range).

OS, overall survival.

*p* \< 0.05.

###### 

Univariate and multivariate analyses of overall survival in metastatic colorectal cancer

  Characteristic           Univariate analysis   Multivariate analysis                                                          
  ------------------------ --------------------- ---------------------------------------------------------- ------------------- ----------------------------------------------------------
  Age, yr                                                                                                                       
   ≤ 65                    1                                                                                1                   
   \> 65                   1.39 (1.23--1.58)     \< 0.001^[a](#tfn16-kjim-2016-348){ref-type="table-fn"}^   1.06 (0.93--1.20)   0.394
  Underlying disease                                                                                                            
   Absent                  1                                                                                \-                  
   Present                 1.03 (0.91--1.17)     0.646                                                      \-                  \-
  Primary tumor location                                                                                                        
   Right colon             1                                                                                1                   
   Left colon              0.80 (0.68--0.94)     0.007^[a](#tfn16-kjim-2016-348){ref-type="table-fn"}^      0.81 (0.68--0.95)   0.010^[a](#tfn16-kjim-2016-348){ref-type="table-fn"}^
   Rectum                  0.76 (0.64--0.90)     0.001^[a](#tfn16-kjim-2016-348){ref-type="table-fn"}^      0.78 (0.64--0.90)   0.001^[a](#tfn16-kjim-2016-348){ref-type="table-fn"}^
  Metastases                                                                                                                    
   Single                  1                                                                                1                   
   Multiple                1.52 (1.34--1.73)     \< 0.001^[a](#tfn16-kjim-2016-348){ref-type="table-fn"}^   1.52 (1.33--1.72)   \< 0.001^[a](#tfn16-kjim-2016-348){ref-type="table-fn"}^
  Surgery                                                                                                                       
   None                    1                                                                                1                   
   Curative surgery        0.22 (0.18--0.27)     \< 0.001^[a](#tfn16-kjim-2016-348){ref-type="table-fn"}^   0.24 (0.20--0.29)   \< 0.001^[a](#tfn16-kjim-2016-348){ref-type="table-fn"}^
   Palliative surgery      0.58 (0.50--0.67)     \< 0.001^[a](#tfn16-kjim-2016-348){ref-type="table-fn"}^   0.58 (0.50--0.67)   \< 0.001^[a](#tfn16-kjim-2016-348){ref-type="table-fn"}^

HR, hazard ratio; CI, confidence interval.

*p* \< 0.05.
